Tyra Biosciences (NASDAQ:TYRA) Trading Up 7.1%

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) traded up 7.1% during mid-day trading on Tuesday . The company traded as high as $21.70 and last traded at $21.65. 12,326 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 145,668 shares. The stock had previously closed at $20.22.

Wall Street Analysts Forecast Growth

TYRA has been the topic of a number of analyst reports. Oppenheimer lowered their target price on Tyra Biosciences from $28.00 to $25.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Thursday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd.

Tyra Biosciences Trading Up 6.3 %

The company’s 50 day simple moving average is $19.02 and its 200 day simple moving average is $17.94. The stock has a market capitalization of $1.13 billion, a PE ratio of -12.90 and a beta of 1.02.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. As a group, analysts predict that Tyra Biosciences, Inc. will post -1.63 EPS for the current year.

Insider Buying and Selling at Tyra Biosciences

In related news, COO Daniel Bensen sold 3,502 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $20.00, for a total transaction of $70,040.00. Following the completion of the transaction, the chief operating officer now owns 427,981 shares of the company’s stock, valued at $8,559,620. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 15.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TYRA. Federated Hermes Inc. raised its holdings in shares of Tyra Biosciences by 1,244.2% in the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock worth $29,000 after purchasing an additional 1,916 shares during the period. AJOVista LLC acquired a new stake in Tyra Biosciences during the 4th quarter worth approximately $59,000. Fishman Jay A Ltd. MI purchased a new position in Tyra Biosciences in the first quarter valued at approximately $246,000. Rhumbline Advisers lifted its position in Tyra Biosciences by 12.3% during the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in Tyra Biosciences by 53.4% during the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock worth $696,000 after buying an additional 17,490 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.